Equities Analysts Issue Forecasts for OVID Q4 Earnings

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a research report issued on Monday, November 17th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings per share of ($0.10) for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. Leerink Partnrs also issued estimates for Ovid Therapeutics' FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.45) EPS, FY2028 earnings at ($0.50) EPS and FY2029 earnings at ($0.50) EPS.

A number of other research analysts have also commented on OVID. Leerink Partners assumed coverage on shares of Ovid Therapeutics in a research note on Monday. They issued an "outperform" rating and a $5.00 price target on the stock. Oppenheimer began coverage on Ovid Therapeutics in a report on Thursday, October 9th. They set an "outperform" rating and a $7.00 price objective for the company. Wall Street Zen downgraded Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Ovid Therapeutics in a report on Wednesday, October 8th. Finally, B. Riley restated a "buy" rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Ovid Therapeutics currently has an average rating of "Buy" and an average price target of $3.92.

View Our Latest Research Report on OVID

Ovid Therapeutics Price Performance

Shares of OVID opened at $1.32 on Wednesday. The company's 50-day moving average is $1.44 and its 200-day moving average is $0.86. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.24 and a quick ratio of 4.24. The firm has a market capitalization of $94.00 million, a PE ratio of -2.64 and a beta of 0.32. Ovid Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.01.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.17 million.

Institutional Investors Weigh In On Ovid Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company's stock worth $53,000 after purchasing an additional 18,841 shares during the last quarter. Private Advisor Group LLC acquired a new position in shares of Ovid Therapeutics during the 3rd quarter worth $33,000. Apollon Wealth Management LLC bought a new stake in shares of Ovid Therapeutics during the 3rd quarter worth $36,000. Persistent Asset Partners Ltd bought a new stake in shares of Ovid Therapeutics during the 3rd quarter worth $60,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Ovid Therapeutics in the third quarter valued at about $69,000. Institutional investors and hedge funds own 72.24% of the company's stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.

Recommended Stories

• Five stocks we like better than Ovid Therapeutics
• Following Congress Stock Trades
• Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum
• What Investors Need to Know to Beat the Market
• What’s on the Thanksgiving Table? A Stock Pick for Every Course
• How to Read Stock Charts for Beginners
• Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ovid Therapeutics Right Now?

Before you consider Ovid Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.

While Ovid Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here